Egetis Therapeutics AB (publ)
STO:EGTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.1
9.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ)
Cash Equivalents
Egetis Therapeutics AB (publ)
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
Cash Equivalents
kr303.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Cash Equivalents
kr1.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cash Equivalents
kr153.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Cash Equivalents
kr925m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
9%
|
CAGR 10-Years
23%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cash Equivalents
kr594m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
0%
|
|
|
BioArctic AB
STO:BIOA B
|
Cash Equivalents
kr611.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Egetis Therapeutics AB (publ)
Glance View
Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
See Also
What is Egetis Therapeutics AB (publ)'s Cash Equivalents?
Cash Equivalents
303.3m
SEK
Based on the financial report for Dec 31, 2023, Egetis Therapeutics AB (publ)'s Cash Equivalents amounts to 303.3m SEK.
What is Egetis Therapeutics AB (publ)'s Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
6%
Over the last year, the Cash Equivalents growth was 138%. The average annual Cash Equivalents growth rates for Egetis Therapeutics AB (publ) have been 2% over the past three years , 6% over the past five years .
You don't have any saved screeners yet